Event in Progress:
Discover the latest content that has just been published on Research Tree
This is the easier task but staying ahead is a tougher one. And, for a tough quarter, management guided in the call that, due to the steep energy price increases in Q1, these would have to be passed on with a one quarter time lag. Another core topic was Lanxess’s preparedness, when it comes to potential embargos / sanctions and other impacts from the Ukraine war. The financials were no big surprise after the release some days ago at first sight, but divulged some interesting details.
Companies: LANXESS AG
AlphaValue
Lanxess’ preliminary figures were above consensus expectations (sales: +8.5%; adjusted EBITDA: +6.8%). This positive development is anticipated to stem from the changes in contract terms allowing for a more stringent roll-over of higher energy prices. Despite this head start, the management made no changes to the guidance.
Lanxess reported some moderate impact on profitability after the strong portfolio rotation. Rightly, the company became a stronger player in the specialities chemicals arena, which gives Lanxess’ EBITDA a certain robustness as it should be clear that margins are not carved in stone. Lanxess reported a good set of figures, strongly beating our top-line expectations (+6.1%) and EBITDA was well ahead. Consensus was partly beaten (top line: +3.2%; adjusted EBTDA: 0%). Current tensions prevented
Despite the consensus-beating Q3 figures, the positive Lanxess’ share price performance has taken a breather. The management flagged a more difficult Q4 and guided to the lower end of the unchanged corridor. We share the management’s view that the factors mentioned will weigh on the figures despite their being part of the business model and the fact that they should be temporary.
Lanxess has taken the opportunity to acquire the Microbial Control business from a leading player in the flavour and fragrance business, which had seen three owners in three years. But this is quite an expensive opportunity once the synergies are stripped out. It looks as if management has some inner understanding of how profitability could be increased and how to stop the personnel drain.
Lanxess’ reported figures were, all in all, quite a re-bounce story, but the operating CF was severely hit by the strong NWC outflow. This was mainly a result of the higher inventories. Nevertheless, the company has shown its resilience and its determination to cushion the negative effects from higher raw material prices. Consensus was beaten by +8.9% at the top line and by +3.9% at EBITDA pre level. The guidance adjustment stemmed mainly from acquisitions’ contributions.
Lanxess has undergone quite a substantial and lengthy restructuring phase to make the company more resilient. The proof it has worked was shown in 2020, but street expectations have also risen. The reported figures were above these, but the beat was quite tiny compared to its peers. Looking at the company’s own expectations, they were at the upper end. ‘Selling’ the narrowing of the previous guidance range as a rise, looks like a marketing gimmick.
One could get the impression that Consumer Protection ‘disinfected’ the group as the company came quite well through the pandemic. Adjusted EBITDA was down 15%, which looks like next to nothing compared to the previous crisis (e.g. the one in 2012/13). The fair answer is that Lanxess looks totally different and the far lower share of cyclical businesses helped to sustain profitability. Our estimates have been clearly beaten on the top line and less pronounced on the profitability levels. Consen
There were some rumours a few weeks ago that Lanxess might be in takeover discussions with the PE firm American Securities. This became a reality today. Contrary to the typical analyst’s reflex, we value the deal as not an expensive one despite management’s strong reference to synergies. In our view, the acquisition of Emerald Kalama makes a lot of sense and fosters Lanxess’s position in its new strong playing field of Consumer Protection, which will absorb ~75% of the quite profitable sales.
Lanxess had a tough Q3. All divisions, except Consumer Protection, suffered from a weaker top line (prices and volumes), which also weighed on margins. However, these divisions saw some recovery with different dynamics. We value the narrowing of the guidance as management’s realistic view on recent developments. The reported figures slightly missed our strong expectations, but fitted with consensus.
Companies: LXS1 LNXSF LXS LXS LXSEUR
Lanxess’ cash pile remained quite high and the pattern of NWC flows gave us no clear indications. Q2 net earnings were positively impacted by the divestment result from the 40% stake sale in Currenta. The group was primarily hit by the lower volumes, except for Consumer Protection. Reported figures were above our expectations, but broadly meet street expectations.
We see management’s actions and the reference to its achievements of the measures made on the portfolio as a bit disconnected. On one hand, Lanxess has great liquidity in a crisis situation since the spin-out from Bayer and, on other hand, it highlighted a more balanced portfolio and lower exposure to the automotive industry. However, it was a smart move to sponge up cash. The Q1 figures came in above our expectations and beat the street’s estimates.
Against the background of the looming COVID-19-driven panic, the Saudi Arabian show-of-force and a rising likelihood of a global recession, we believe Lanxess’s 2020 guidance does not include all the negative impacts as some are really quite recent. We appreciate management’s efforts to guide for potential COVID-19 effects. Lanxess’s figures came in fully in line with our operational expectations, especially on the profitability levels that we were focusing on. Consensus was partly beaten and it
Lanxess seems to have left the path of strong cyclicality and the respective impact on profitability. Nevertheless, the company could not completely decouple from the economic environment as Engineering Materials recorded lower margins. Reported figures were stronger than expected, especially on the profitability line, but full matched the street’s expectations.
Back in 2014, prior to Mr Zachert taking over, the current harsh environment would have had a significantly negative impact on the figures. For the current-day Lanxess, these negative impacts were not that strong as prices remained quite stable in Q2. The reported figures were a notch above our expectations and in line with consensus.
Research Tree provides access to ongoing research coverage, media content and regulatory news on LANXESS AG. We currently have 1 research reports from 2 professional analysts.
Strix has reported FY23 results to 31 December 2023 with adjusted PAT of £20.1m, in line with our updated forecast and company guidance provided in January. Revenue grew 35.2% to £144.6m, benefitting from the full year inclusion of the Billi acquisition, albeit slightly below our forecast of £151.0m. Its core Kettle Controls division also performed robustly, growing 2.7%, ahead of the broader market and indicating market share gain. Recent acquisitions have noticeably improved the Group’s growth
Companies: Strix Group PLC
Zeus Capital
Companies: Yu Group PLC
Liberum
Companies: FOG PEB KBT EMR TIME GETB JNEO
Cavendish
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
Cohort announces that its subsidiary SEA (Systems Engineering and Assessment Ltd.) has been awarded a major contract by the UK’s Ministry of Defence to provide Electronic Warfare Counter Measures (Increment 1a) (EWCM 1a) to the Royal Navy with a total value of at least £135m. This includes provision and support of SEA’s Trainable Decoy Launcher System, Ancilia. At the FY 24 interim results Cohort had commented on an overall “increased tempo” of order intake. The Group reported a closing order b
Companies: Cohort plc
Equity Development
Positives emerged, particularly in H2, as the recovery commenced within the kettle controls market. Billi was the architect of the revenue improvement, with LAICA also delivering a double-digit increase in the top line. Margins improved, notwithstanding a change in the mix. Encouragingly, investor concerns on debt were allayed with the careful management of cash, and latterly as bankers raised the net debt/EBITDA covenant to 2.75x. With further emphasis on costs and cash conservation and a lik
Companies: Luceco PLC
Companies: FOG TND BVXP ACC HDD
Quadrise continues to advance towards commercial revenues for its innovative fuel and biofuel technologies, with each of its projects approaching key milestones in 2024. Preparatory steps for the MSC Shipmanagement (MSC) fuel trials are now complete and fuel supply agreements are nearing finalisation. Quadrise will achieve its first licensing revenues on the successful completion of Valkor’s project financing (timing uncertain). Quadrise also successfully concluded its Morocco trial, paving the
Companies: Quadrise PLC
Edison
Companies: Flowtech Fluidpower plc
Judges Scientific is a group involved in the buy and build of scientific instrumentation businesses. Testament to the strength of its highly engineered offer and global diversified customer base, total revenue increased an impressive 20.2% to £136.1m (organic +15%), with adj. PBT +7.5% to £31.7m (FY2022: £28.3m), 3.1% ahead of our estimate of £30.5m. Fully diluted (FD) adjusted EPS increased a more muted 2.6% (impacted by anticipated tax headwinds) to 368.5p (basic adj EPS 374.5p), 3.4% ahead of
Companies: Judges Scientific plc
WHIreland
Companies: Michelmersh Brick Holdings PLC
Canaccord Genuity
Companies: BILN IGP RBN SBTX
Gelion has reported in line H1 FY24 results that demonstrate continued strong cash management and steady progress in its pursuit of next generation lithium-sulphur battery technologies. Encouraging early test results justify last year’s IP acquisitions and validate Gelion’s Li-S battery technology plan, with additional progress expected to be reported in H2 alongside its pursuit of a strategic partner for its planned Advanced Commercial Prototyping Centre (ACPC) facility in Australia. There is a
Companies: Gelion PLC
Forterra’s FY23 (to 31 December) earnings were slightly higher than guidance, which was raised in January, with resilient pricing partly offsetting a steep fall in demand among its main end users, large housebuilders. Our estimates are broadly unchanged, other than reflecting a more conservative stance on the final dividend. Despite a cautious tone in the outlook statement, we believe the largest housebuilders may now rebound more strongly than smaller peers.
Companies: Forterra Plc
Progressive Equity Research
Share: